A first for Samsung: a woman not among its founders appointed CEO.
INCHEON, South Korea, Nov. 27, 2024 — Samsung Bioepis Co., Ltd. announced that Kyung-Ah Kim, formerly Executive Vice President and Development Division Leader, has been appointed President and Chief Executive Officer. Kim succeeds Christopher Hansung Ko, who will head Samsung’s Future Business Division.
With over 20 years’ experience in biological development, Dr. Kim led Samsung Bioepis’ Development Division since December 2021, overseeing all product development across various therapeutic areas. Since joining in December 2015, she’s held several leadership roles within the division. Before Samsung Bioepis, she was a Principal Scientist and Vice President at Samsung Advanced Institute of Technology (SAIT), leading the Biotherapeutics Group focused on antibody therapeutics for oncology. Earlier in her career, she held scientific and leadership positions at various biopharmaceutical companies, managing projects encompassing genetic sequencing, drug screening assays, pre-clinical and pharmacological assessments, and antibody functional assessments.
Dr. Kim earned a Ph.D. in neurotoxicology from The Johns Hopkins University, where her research focused on signal transduction pathways in learning impairment caused by genetic perturbation in lead poisoning.
About Samsung Bioepis Co., Ltd.
Founded in 2012, Samsung Bioepis is a biopharmaceutical company dedicated to accessible healthcare. Through innovative product development and a commitment to quality, it aims to be a global biopharmaceutical leader. Samsung Bioepis is developing a range of biosimilar candidates across immunology, oncology, ophthalmology, hematology, and endocrinology. For more information, please visit: and follow us on social media – , .
MEDIA CONTACT
Anna Nayun Kim, Yoon Kim,
“`